Advertisement

Postmenopausal Osteoporosis

  • Patrícia Nunes MesquitaEmail author
  • Juliana Maria Coelho Maia
  • Francisco Bandeira
Chapter

Abstract

Osteoporosis is a osteoid-metabolic disorder that affects many people with high prevalence in postmenopausal women. It is a disease that has a great impact on quality of life, due to high risk of fractures and a public health problem by raising health costs, mainly because it is still undiagnosed and undertreated, despite the current recommendations to routinely investigate women over 65 years of modern therapeutic modalities. In this chapter we will review ways of diagnosing and treatining postmenopausal osteoporosis.

Keywords

Bone Mineral Density Postmenopausal Woman Lumbar Spine Femoral Neck Vertebral Fracture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ac L, Orwol ES, Jonhston CC, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–8.CrossRefGoogle Scholar
  2. 2.
    Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. 2011;155(11):751–61. doi: 10.1059/0003-4819-155-11-201112060-00007.PubMedCrossRefGoogle Scholar
  3. 3.
    Bandeira F, Carvalho EF. Prevalência de osteoporose e fraturas vertebrais em mulheres na pós-menopausa atendidas em serviços de referência. Rev Bras Epidemiol. 2007;10(1):86–98.CrossRefGoogle Scholar
  4. 4.
    Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010; 17(1): 25–54.Google Scholar
  5. 5.
    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, et al. Does osteoporosis therapy invalidate FRAX for frature prediction? J Bone Miner Res. 2012;27(6):1243–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Siminoski K, Jiang G, Adachi JD, Hanley DA, Cline G, Ioannidis G, et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int. 2005;16(4):403–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Genant HK, Wu CY, Van Kujik C, Nevitt MC. Vertebral fracture assessment using semiquantitative technique. J Bone Miner Res. 1993;8(9):1137–48.PubMedCrossRefGoogle Scholar
  9. 9.
    Genant HK, Engelke K, Fuerst T, Glüer CC, Grampp S, Harris ST, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996;11(6):707–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1–129.Google Scholar
  11. 11.
    Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM. Summary of the International Society For Clinical Densitometry 2005 position development conference. J Bone Miner Res. 2007; 22(5):643–5.PubMedCrossRefGoogle Scholar
  12. 12.
    National Institutes of Health. NIH consensus statement: osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17(1):1–45.Google Scholar
  13. 13.
    Eventov I, Frisch B, Cohen Z, Hammel I. Osteopenia, hematopoiesis, and bone remodelling in iliac crest and femoral biopsies: a prospective study of 102 cases of femoral neck fractures. Bone. 1991;12(1): 1–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Meadows ES, Mitchell BD, Bolge SC, Johnston JA, Col NF. Factors associated with treatment of women with osteoporosis or osteopenia from a national survey. BMC Womens Health. 2012;12:1.PubMedCrossRefGoogle Scholar
  15. 15.
    NOF’s new clinician’s guide to prevention and treatment of osteoporosis. 2008. Accessed 22 Aug 2012. Available at: http://www.nof.org/professionals/Clinicians_Guide.html
  16. 16.
    Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736.PubMedCrossRefGoogle Scholar
  17. 17.
    Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012;367:1.CrossRefGoogle Scholar
  18. 18.
    Kemmler W, von Stengel S, Engelke K, Häberle L, Kalender WA. Exercise effects on bone mineral density, falls, coronary risk factors, and health care costs in older women: the randomized controlled senior fitness and prevention (SEFIP) study. Arch Intern Med. 2010;170:179.PubMedCrossRefGoogle Scholar
  19. 19.
    Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011;7, CD000333.PubMedGoogle Scholar
  20. 20.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996; 276(17):1389–96Google Scholar
  22. 22.
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Banks E, Beral V, Reeves G, Balkwill A, Balkwill A, Barnes I, Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA. 2004;291(18):2212–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697–708.PubMedCrossRefGoogle Scholar
  25. 25.
    Chesnut 3rd CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109(4):267–76.PubMedCrossRefGoogle Scholar
  26. 26.
    Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int. 2012;23(1):17–38. Epub 2011 Jun 10.PubMedCrossRefGoogle Scholar
  27. 27.
    Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37.PubMedCrossRefGoogle Scholar
  28. 28.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–45.PubMedCrossRefGoogle Scholar
  29. 29.
    Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003;33(4):522–32.PubMedCrossRefGoogle Scholar
  30. 30.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res. 2005;20(9):1514–24. Epub 2005 May 16.PubMedCrossRefGoogle Scholar
  31. 31.
    Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Raloxifene and risk for stroke based on the Framingham stroke risk score. Am J Med. 2009;122(8):754–61. Epub 2009 Jun 18.PubMedCrossRefGoogle Scholar
  32. 32.
    Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med. 2004;255(4):503–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med. 2004;164(8):871–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, et al. Effect of Raloxifene on all-cause mortality. Am J Med. 2010;123(5):469. e1–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD. Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol. 2008;26(32):5227–32. Epub 2008 Oct 6.PubMedCrossRefGoogle Scholar
  36. 36.
    Archer DF, Pinkerton JV, Utian WH, Menegoci JC, de Villiers TJ, Yuen CK, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009;16(6):1109–15.PubMedCrossRefGoogle Scholar
  37. 37.
    Becker C. Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med. 2010;362(8):752–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97(7):2272–82. Epub 2012 Apr 20.PubMedCrossRefGoogle Scholar
  39. 39.
    Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008;23(11):1712–21.PubMedCrossRefGoogle Scholar
  40. 40.
    Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010;363(21):2027–35.PubMedCrossRefGoogle Scholar
  41. 41.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–41.PubMedCrossRefGoogle Scholar
  42. 42.
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risendronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83–91.PubMedCrossRefGoogle Scholar
  43. 43.
    Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone. 1996;19(5):527–33.PubMedCrossRefGoogle Scholar
  44. 44.
    McClung M. Bisphosphonates: review article. Arq Bras Endocrinol Metab. 2006;50(4):735–44.CrossRefGoogle Scholar
  45. 45.
    Carvalho NNC, Voss LA, Almeida MOP, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011;96(9):2675–80. Epub 2011 Jul 13.PubMedCrossRefGoogle Scholar
  46. 46.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis (HORIZON). N Engl J Med. 2007;356(18):1809–22.PubMedCrossRefGoogle Scholar
  47. 47.
    Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis—For whom and for how long? N Engl J Med. 2012;366(22):2051–3. Epub 2012 May 9.PubMedCrossRefGoogle Scholar
  48. 48.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.PubMedCrossRefGoogle Scholar
  49. 49.
    McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24(1):227–35. doi: 10.1007/s00198-012-2052-4.PubMedCrossRefGoogle Scholar
  50. 50.
    Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2): 222–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153–61.PubMedCrossRefGoogle Scholar
  52. 52.
    Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72–81.PubMedCrossRefGoogle Scholar
  53. 53.
    Kendler DL, Bessette L, Hill CD, Gold DT, Horne R, Varon SF, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int. 2010;21(5):837–46.PubMedCrossRefGoogle Scholar
  54. 54.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.PubMedCrossRefGoogle Scholar
  55. 55.
    Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164(18):2024–30.PubMedCrossRefGoogle Scholar
  56. 56.
    Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006;91(4):1370–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1838–45.PubMedCrossRefGoogle Scholar
  58. 58.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):503–11.PubMedCrossRefGoogle Scholar
  59. 59.
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353(6):555–65.PubMedCrossRefGoogle Scholar
  60. 60.
    Adami S, San Martin J, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP, et al. Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int. 2008;19(1):87–94.PubMedCrossRefGoogle Scholar
  61. 61.
    Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009;24(4):726–36.PubMedCrossRefGoogle Scholar
  62. 62.
    Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008;42(1):129–38.PubMedCrossRefGoogle Scholar
  63. 63.
    Girotra M, Rubin MR, Bilizikian JP. Anabolic skeletal therapy for osteoporosis. Arq Bras Endocrinol Metab. 2006;50(4):745–54.CrossRefGoogle Scholar
  64. 64.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5): 459–68.PubMedCrossRefGoogle Scholar
  65. 65.
    Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90(5):2816–22.PubMedCrossRefGoogle Scholar
  66. 66.
    O’Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 2006;3, CD005326.PubMedGoogle Scholar
  67. 67.
    Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int. 2012;23(3):1115–22.PubMedCrossRefGoogle Scholar
  68. 68.
    Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5):937–47.PubMedGoogle Scholar
  69. 69.
    Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26(2): 242–51.PubMedCrossRefGoogle Scholar
  70. 70.
    Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578–88.PubMedCrossRefGoogle Scholar
  71. 71.
    Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25(5):948–59.PubMedCrossRefGoogle Scholar
  72. 72.
    Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26.PubMedCrossRefGoogle Scholar
  73. 73.
    Cosman F, Lane NE, Bolognese MA, Zanchetta JR, Garcia-Hernandez PA, Sees K, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010;95(1):151–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J Bone Miner Res. 2012;27(8):1821–9. doi: 10.1002/jbmr.1602.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Patrícia Nunes Mesquita
    • 1
    Email author
  • Juliana Maria Coelho Maia
    • 2
  • Francisco Bandeira
    • 3
  1. 1.Department of EndocrinologyAgamenon Magalhaes HospitalRecifeBrazil
  2. 2.Department of EndocrinologyAgamenon Magalhaes HospitalRecifeBrazil
  3. 3.Division of Endocrinology and DiabetesUniversity of Pernambuco Medical School, Agamenon Magalhães Hospital, State Department of Health/SUS/UPERecifeBrazil

Personalised recommendations